Watch Episode #177 Some scientific breakthroughs don’t start with a grant or a perfectly architected They start with a chance email, an unexpected visitor at the door, or the moment a team realizes the Their collaboration didn’t start as a big strategic play. It started with curiosity, openness, and the humility to admit that better answers required better tools this story resonates with your work or curiosity, go deeper. 🎧 Listen to the full conversation with Dr

For Dr. GPCR News, please subscribe to your monthly newsletter. Research Fellow - School of Physics and Astronomy Postdoctoral Research Associate (Fixed Term) Explore Dr

Explore Dr. GPCR Ecosystem

Industry News Arcoscreen selected by START Lausanne to pitch at the START Global summit on the 23-24th Receptor 2 In Diabetic Retinopathy PhD Opportunity - Novel P2y Receptor Ligands For Drug Discovery Explore Dr

Dr.

postdoctoral training at Boston Children’s Hospital and Harvard Medical School, he joined the lab of Dr Starting Blue wasn’t glamorous.

At Dr. GPCR, we recognized this core problem.

These assays are available from Eurofins DiscoverX, Dr.

It's starting to look a lot like Christmas at Dr. GPCR!

Explore Dr. GPCR Ecosystem

Monthly AMAs  where you can challenge Dr. Kenakin with your own enzyme or GPCR interaction puzzles.

, you’re also unlocking over 500 minutes of exclusive, expert-led content from thought leaders like Drs

The reverse pharmacology approach — starting from a synthetic ligand with measurable receptor activity For a more detailed discussion of these concepts and additional expert perspectives from Dr.

of Staff Postdoctoral Fellow, Biochemical And Cellular Pharmacology Project Leader, Biology Explore Dr

Receptor 2 In Diabetic Retinopathy PhD Opportunity - Novel P2y Receptor Ligands For Drug Discovery Explore Dr

Thrilling beginning to Principles of Pharmacology I We are excited to announce the start of our Principles live and work  in a developing country, please complete this form to enjoy complimentary access to Dr

Developing Nations If you reside and work in a developing country, complete this form for free access to Dr

Developing Nations If you reside and work in a developing country, complete this form for free access to Dr

Explore Dr. GPCR Ecosystem

postdoctoral training, I joined one of the labs that participated in Latrophilins’ discovery, the lab of Dr Thomas Südhof, but did not start working on them right away.

Explore Dr. GPCR Ecosystem

Dr.

In reality, something more subtle starts to shift. 👉 Decision-making changes. Plans that once felt flexible start to feel constrained. Roadmaps stop being tools for choice and start becoming tools for justification. Strategic takeaway 👉 For biotech founders , financial failure rarely starts with an empty bank account It starts when financial control fades without being noticed . 👉 The key shift is not better reporting

doesn’t immediately tell them who it’s for, why it matters, and what makes it different, then they start They have to guess why it matters, what the application is, and whether it fits. ✅ Start with relevance People start leaning in. You stop explaining. People start connecting the dots for you. 👉 This is what clarity creates. Start refining your message. Ready to Break Your Bottlenecks?

struggling to predict structures from scratch, Alessandro and others could now use AI-generated models as starting “…now you have a plethora of 400 models that you can start with molecular dynamics, docking, virtual Start with our GPCR training program and get hands-on with virtual tools shaping the future of drug discovery

Yet over time, alignment fades, and decisions start to feel disconnected. 👉 Many founders ask why biotech startups fail  not after a collapse, but when the company starts to feel harder to run without a clear decisions The turning point for many biotech startups comes when strategy stops being a document and starts Instead of adding more work to feel safer, teams start designing fewer experiments with sharper intent trusts execution because work is clearly tied to strategic intent. ✅ The company stops reacting and starts

When too many priorities advance in parallel, focus starts to diffuse. Resources stretch. When Everything Is Strategic, Nothing Is Decisive 👉 Strategic overload starts with reasonable decisions From the outside, investors start to ask subtle questions. What is the real bet? Yet the hardest strategic decisions are rarely about starting something new. diluted commitment. 👉 Biotech fundraising reflects the structure of your strategy long before you start

Where Biotech Misalignment Starts 👉 Most misalignment doesn’t start with conflict. It starts with silence. You assume your CSO knows where you’re headed. Your BD person starts framing it for a niche diagnostic use. The board expects an IND package. Real biotech traction starts when decisions are driven by shared strategy, not disconnected deliverables tradeoffs, or simply feeling stuck, this session will get you unstuck — fast. 👉 Book a 1:1 consult and start

Starting From Zero: Growing With a Mentor When Alessandro joined Prof. At the start it was difficult, because you see all these projects and you think, ah, I don’t know… but

consistency: Can you show that your process will be scalable, repeatable, and GMP-compliant from the start Reverse Engineering Your Path to FDA Approval Most biotech development plans are built forward : start They start by asking: What would FDA approval actually require from us, and what decisions need to reflect Instead of collecting interesting data, you start collecting strategic evidence . tradeoffs, or simply feeling stuck, this session will get you unstuck — fast. 👉 Book a 1:1 consult and start